---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-013587"
form_type: "8-K"
ticker: "HRTX"
cik: "0000818033"
company_name: "HERON THERAPEUTICS, INC. /DE/"
filed_at: "2024-01-24T23:59:59+00:00"
generated_at: "2026-06-06T19:38:42.422322+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Heron Therapeutics gets FDA approval for ZYNRELEF indication expansion covering 13M annual procedures

## Summary
- FDA approved supplemental NDA for ZYNRELEF to include soft tissue and orthopedic surgical procedures, including foot and ankle.
- Expanded indication now covers an estimated 13 million procedures annually, an 86% increase over prior indicated procedures.
- No unique safety issues identified in new clinical trials for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
- CEO Craig Collard highlights label expansion, CrossLink partnership, and potential VAN approval as transformative for ZYNRELEF.

## SEC filing metadata
- accession: 0001193125-24-013587
- form_type: 8-K
- ticker: HRTX
- cik: 0000818033
- company_name: HERON THERAPEUTICS, INC. /DE/
- filed_at: 2024-01-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818033/000119312524013587/0001193125-24-013587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818033/000119312524013587/d626508d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-013587
- JSON: https://secwatch.observer/filing/0001193125-24-013587.json
- Plain text: https://secwatch.observer/filing/0001193125-24-013587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.